TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from SkinBioTherapeutics ( (GB:SBTX) ) is now available.
SkinBioTherapeutics plc has announced the posting of its Annual Report and Accounts for the year ending 30 June 2025, alongside the Notice of its Annual General Meeting (AGM) scheduled for 29 December 2025. The company continues to strengthen its position in the skin health industry through strategic partnerships and acquisitions, aiming to enhance its market presence and operational capabilities. This announcement underscores its commitment to transparency and growth, potentially impacting stakeholders positively by expanding its product reach and technological applications.
The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Underperform.
SkinBioTherapeutics faces significant financial challenges with ongoing losses and cash burn, which heavily influence its stock score. While technical indicators show bearish trends, recent positive corporate events and strategic moves offer potential future benefits. However, until these translate into improved financial performance, the stock’s score remains low.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a life science company focused on skin health, leveraging its proprietary platform technology, SkinBiotix®, developed by the University of Manchester’s dermatology team. The company targets the skin healthcare market through five pillars, with a focus on cosmetic skincare and food supplements addressing the gut-skin axis. It collaborates with Croda plc for its SkinBiotix® technology and offers AxisBiotix™ products for inflammatory skin conditions. The company is expanding through acquisitions in skincare and cosmetics, enhancing distribution and manufacturing capabilities.
Average Trading Volume: 914,068
Technical Sentiment Signal: Sell
Current Market Cap: £39.14M
Find detailed analytics on SBTX stock on TipRanks’ Stock Analysis page.